Press Releases

CPhI Conferences India, a division of Informa Markets in India is back with the most influential show, the 11th Annual InnoPack Pharma Confex slated for 9th and 10th June 2022 at Sahara Star, Mumbai, presented by West Pharma. The show will offer a unique combination of an exhibition floor, semi-scientific conferences, and a dedicated spotlight for innovations allowing the pharma packaging fraternity to discover the latest trends and revolutionary technologies transforming the packaging indust

Thermo Fisher Scientific Inc., the world leader in serving science, and TransMIT GmbH Center for Mass Spectrometric Developments have announced a co-marketing agreement to promote the use of a mass spectrometry imaging (MSI) platform for spatial multi-omics applications in pharma and clinical labs. As part of the relationship, TransMIT will combine its proprietary scanning microprobe matrix-assisted laser desorption/ionization (SMALDI) MSI and 3D-surface MSI technology with the exce

COVID-19 patients with both type 2 diabetes mellitus  and cardiovascular disease  showed significantly higher rates of mortality, intensive care unit (ICU) admissions, and hospitalizations compared to COVID-19 patients with neither T2DM nor CVD. The study, by HealthCore, Inc., Boehringer Ingelheim and Anthem, Inc. – soon to be Elevance Health on June 28 -- also found the cost per patient was higher in COVID-19 patients with T2DM and CVD compared to individuals without either d

AM-Pharma BV, an emerging leader specializing in the development of treatments for serious diseases, today announced that Lars Boesgaard, Chief Financial Officer, is to present at the Jefferies Healthcare Conference, to be held in New York on Wednesday, June 8, 2022 at 8:00 a.m. (Eastern Time). About AM-Pharma AM-Pharma's goal is to save and improve the lives of patients facing serious illnesses. Our initial focus is acute kidney injury associated with

Zealand Pharma A/S , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today presented data from its Phase 1 trial of dapiglutide at the 82nd Scientific Sessions of the American Diabetes Association (ADA) in New Orleans and announced it will be supporting a Phase 2 investigator-initiated clinical trial of dapiglutide in obesity anticipated to commence by early 2023. The Phase 1 results of dapiglutide, a GLP-1R/GLP-2R dual agonist

Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced the completion of its Phase 1 clinical trial of TQS-168, a small molecule modulator of PGC-1a in development for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Single and multiple doses of TQS-168 were well tolerated in 78 h

12.7 million Americans aged 65 and older are projected to have Alzheimer’s dementia by 2050. LUCID and JT are now partnering on the development of a prescription digital therapeutic for Alzheimer’s disease. Alzheimer’s is more than just memory loss – neuropsychiatric symptoms can include anxiety, aggression and personality changes. These symptoms aren’t just heartbreaking, they’re promoting the burnout of caregivers. Treatment is more necessary th

4P-Pharma, a French clinical stage biotechnology company, and Delta 4, an Austrian digital drug development company, today announced the signing of a collaboration agreement. Under the agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no effective curative treatment is available. Contributing to this collaboration, Delta 4 will apply its proprietary computational and iterative bi

Navigo Proteins GmbH (“Navigo”), a premier protein engineering company and developer of affinity ligands for custom chromatography solutions, today announces successful development of an affinity resin for the capture of an undesired contaminant from the baculovirus insect cell expression system, namely the glycoprotein gp64. Navigo successfully leveraged the Precision Capturing® technology to develop a Precision X ligand binding to the gp64 contaminant. The innovative resin w

Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been selected by AmyriAD Pharma to provide CDMO services to support the ongoing clinical development of AD101. The compound, a novel T-type calcium channel modulator, is currently in clinical development for the treatment of Alzheimer’s disease (AD). AmyriAD